Combined Company to Trade on NASDAQ Post-closing under Tickers: RVPH and RVPHW NEW YORK and CUPERTINO, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (“Reviva Holdings”), as the successor to Tenzing Acquisition Corp., a special purpose acquisition company incorporated in the British Virgin Islands (“Tenzing”) (NASDAQ: TZAC), and Reviva Pharmaceuticals, Inc., a Delaware corporation (“Reviva”), a California-based clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced the compl

424B3 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)

10-Q - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)

424B4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)

EFFECT - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)

SC 13G/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

S-1/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)

SC 13G/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

S-1 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)

4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Issuer)

4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Issuer)